Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07134998) titled 'Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations' on Aug. 14.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Condition:
Advanced KRAS G12D Mutant Solid Tumors
Intervention:
Drug: HRS-6093
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 2025
Target Sample Size: 153
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT...